STM JOURNALS

International Journal of
Antibiotics

https://journals.stmjournals.com/ijab

ISSN:2584-2986
Volume 3, Issue 2, 2026
July–December
DOI (Journal): 10.37591/IJAB

Review IJAB

Influence of Antibiotic Promotion Practices on Pharmacovigilance and Resistance Reporting Patterns

Suraj Sen[1], Anit Jha[2], Rajeev Ratan[3,*], Deepak[4], Nitesh Kumar[4], Azad[4]

Abstract

The global escalation of antimicrobial resistance (AMR) has emerged as a critical public health crisis, undermining decades of therapeutic advancements. While inappropriate prescribing and misuse of antibiotics are widely acknowledged contributors, the role of pharmaceutical promotion practices remains underexplored in influencing prescribing behaviors and downstream pharmacovigilance systems. This review critically examines how antibiotic promotion strategies – ranging from direct physician engagement to digital marketing – affect adverse drug reaction (ADR) reporting and resistance surveillance patterns. The article integrates insights from pharmacovigilance frameworks, antimicrobial stewardship programs, and healthcare marketing ethics to evaluate the multidimensional impact of promotional activities. Evidence suggests that aggressive marketing may skew prescription trends toward newer, broad-spectrum antibiotics, potentially leading to underreporting of ADRs and delayed resistance detection. Furthermore, promotional bias may influence clinicians' perception of drug safety, thereby affecting spontaneous reporting systems. This review also highlights systemic gaps in pharmacovigilance reporting, particularly in low- and middle-income countries, where regulatory oversight is limited and promotional influence is often stronger. Mechanistic pathways linking promotion practices to resistance reporting distortions are discussed, including cognitive bias, selective information dissemination, and economic incentives. The study concludes by emphasizing the need for stricter regulatory frameworks, enhanced transparency in pharmaceutical marketing, and integration of pharmacovigilance with antimicrobial stewardship initiatives. Strengthening these systems is essential to ensure rational antibiotic use and accurate resistance monitoring, ultimately safeguarding global health.

Keywords: Antibiotic promotion, pharmacovigilance, antimicrobial resistance, adverse drug reaction reporting, pharmaceutical marketing, antimicrobial stewardship, drug safety surveillance

***Author for Correspondence**
Rajeev Ratan
E-mail: rajeevsinghrathourjnp2000@gmail.com

[1]Principal, Department of Pharmacy, Harishchandra Pharmacy College, Jaunpur, Uttar Pradesh, India
[2]Academic Head, Department of Pharmacy, Harishchandra Pharmacy College, Jaunpur, Uttar Pradesh, India
[3]Assistant Professor, Department of Pharmacy, Harishchandra Pharmacy College, Jaunpur, Uttar Pradesh, India
[4]Scholar, Department of Pharmacy, Harishchandra Pharmacy College, Jaunpur, Uttar Pradesh, India

Received Date: May 04, 2026
Accepted Date: May 07, 2026
Published Date: May 20, 2026

Citation: Suraj Sen, Anit Jha, Rajeev Ratan, Deepak, Nitesh Kumar, Azad. Influence of Antibiotic Promotion Practices on Pharmacovigilance and Resistance Reporting Patterns. International Journal of Antibiotics. 2026; 3(2): 1–11p.

INTRODUCTION

Antibiotics have revolutionized modern medicine, significantly reducing morbidity and mortality associated with infectious diseases. However, their widespread and often irrational use has contributed to the rapid emergence of antimicrobial resistance (AMR), posing a significant threat to global healthcare systems. While clinical misuse and patient non-compliance are frequently cited causes, the influence of pharmaceutical promotion on prescribing behavior is an equally important yet insufficiently addressed factor [1].

Pharmaceutical companies employ various promotional strategies to increase the market share of their antibiotic products. These strategies include medical representative visits, sponsored conferences, free drug samples, continuing medical education

(CME) programs, and digital marketing campaigns. Although these practices aim to inform healthcare professionals about new therapeutic options, they may inadvertently bias prescribing decisions, often favoring newer, expensive, or broad-spectrum antibiotics over established, guideline-recommended therapies.

The interplay between antibiotic promotion and pharmacovigilance is particularly complex. Pharmacovigilance systems rely heavily on spontaneous reporting of adverse drug reactions (ADRs) by healthcare professionals. However, promotional practices may shape clinicians' perceptions of drug safety and efficacy, potentially leading to underreporting or selective reporting of ADRs. This distortion can compromise the integrity of drug safety databases and delay the identification of safety signals (Figure 1) [2, 3].



Figure 1. Interrelationship between antibiotic promotion, prescribing behavior, and pharmacovigilance.

Understanding the influence of antibiotic promotion on pharmacovigilance and resistance reporting is essential for developing effective interventions. This review aims to explore these relationships in depth, beginning with a comprehensive examination of the historical and conceptual background of antibiotic promotion practices. (Table 1)

Table 1. Key components influencing antibiotic use and reporting systems.

Component	Description	Impact on healthcare system
Pharmaceutical Promotion	Marketing strategies targeting prescribers	Alters prescribing patterns.
Prescribing Behavior	Clinician decision-making in antibiotic selection	Affects drug utilization trends.
Pharmacovigilance Systems	Monitoring and reporting of ADRs	Ensures drug safety.
Resistance Surveillance	Tracking antimicrobial resistance patterns	Guides treatment guidelines.
Regulatory Framework	Policies governing drug promotion and reporting	Maintains ethical standards.

BACKGROUND / LITERATURE REVIEW

Evolution of Antibiotic Promotion Practices

The promotion of antibiotics has evolved significantly over the past century, paralleling advancements in pharmaceutical sciences and marketing strategies. In the early days of antibiotic discovery, such as the introduction of Penicillin, promotion was largely informational, focusing on the revolutionary therapeutic benefits of these agents. However, as the market became saturated with multiple antibiotic classes, competition intensified, leading to more aggressive and persuasive marketing approaches [4–6].

During the late 20th and early 21st centuries, pharmaceutical promotion shifted toward relationship-based marketing. Medical representatives became key intermediaries between pharmaceutical companies and healthcare professionals. These representatives provided drug samples, sponsored educational events, and offered incentives to encourage the prescription of specific antibiotics [5].

In recent years, digital transformation has further reshaped promotional strategies. Online platforms, webinars, targeted advertisements, and electronic detailing have expanded the reach of pharmaceutical marketing. While these innovations improve access to information, they also raise concerns about the quality and objectivity of the content delivered [7, 8].

Pharmacovigilance Systems and Their Importance

Pharmacovigilance is defined as the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. National and international pharmacovigilance programs, such as the Uppsala Monitoring Centre, play a crucial role in maintaining drug safety.

These systems rely heavily on spontaneous reporting by healthcare professionals, patients, and pharmaceutical companies. However, underreporting remains a significant challenge, with estimates suggesting that only a small fraction of ADRs are reported. Factors contributing to underreporting include lack of awareness, time constraints, fear of legal consequences, and uncertainty about causality [9–12].

Promotional practices can exacerbate these challenges by influencing the perception of drug safety. If clinicians are exposed primarily to positive information about a drug, they may be less likely to associate observed adverse events with that medication, thereby reducing reporting rates. (Table 2)

Table 2. Evolution of antibiotic promotion strategies.

Time period	Promotion strategy	Key features
Early 20th Century	Informational Promotion	Focus on discovery and therapeutic benefits.
Mid 20th Century	Print and Direct Advertising	Brochures, journals, and medical detailing.
Late 20th Century	Relationship Marketing	Medical representatives, incentives, sponsorships.
21st Century	Digital and Data-Driven Marketing	Online platforms, targeted ads, e-detailing.

Antimicrobial Resistance: A Global Perspective

Antimicrobial resistance arises when microorganisms evolve mechanisms to withstand the effects of antibiotics. This phenomenon is accelerated by the overuse and misuse of antibiotics, often driven by inappropriate prescribing practices [13].

The emergence of resistant pathogens such as Methicillin-resistant Staphylococcus aureus highlights the severity of the problem. Resistance not only compromises treatment outcomes but also increases healthcare costs, prolongs hospital stays, and elevates mortality rates. (Figure 2)

Influence of Pharmaceutical Promotion on Prescribing Behavior

A substantial body of literature demonstrates that pharmaceutical promotion significantly affects prescribing patterns among healthcare professionals. Studies across various healthcare systems indicate that frequent interactions with medical representatives are associated with increased prescription rates of promoted antibiotics, often irrespective of clinical necessity.

Promotional activities tend to emphasize newer-generation antibiotics, such as Ciprofloxacin and Azithromycin, due to their higher profit margins and broader therapeutic indications. While these drugs are clinically valuable, their overuse can accelerate resistance development and diminish their long-term effectiveness [14].



Figure 2. Development of antimicrobial resistance due to antibiotic misuse.

Healthcare professionals may not always recognize the extent of influence exerted by promotional activities. Cognitive biases, such as reciprocity (accepting gifts or incentives) and familiarity (repeated exposure to a drug name), can subtly shape prescribing decisions. These biases are often reinforced through sponsored educational programs and industry-funded clinical data.

CLASSIFICATION / TYPES OF ANTIBIOTIC PROMOTION PRACTICES

Pharmaceutical promotion encompasses a wide spectrum of strategies designed to influence the prescribing behavior of healthcare professionals. These practices can be broadly classified based on their mode of delivery, target audience, and level of direct interaction. Understanding these classifications is essential for analyzing how different promotional approaches impact pharmacovigilance and antimicrobial resistance reporting [15].

Direct Promotion to Healthcare Professionals

Direct promotion remains one of the most influential methods employed by pharmaceutical companies. It involves personal interactions between company representatives and prescribers.

Medical Representative Detailing

Medical representatives provide drug information, distribute samples, and highlight product advantages. These interactions are often tailored to individual prescribers and may include persuasive communication techniques.

Sponsored Continuing Medical Education (CME)

Pharmaceutical companies frequently sponsor educational programs that provide clinical updates. While these programs contribute to knowledge dissemination, they may also introduce subtle biases favoring specific antibiotics [16–18].

Free Samples and Incentives

Provision of free antibiotic samples, gifts, or financial incentives can influence prescribing patterns through psychological mechanisms such as reciprocity.

Indirect Promotion Strategies

Indirect promotional practices target broader audiences and often operate through less obvious channels.

Medical Journals and Publications

Pharmaceutical companies may sponsor research publications or advertisements in scientific journals. Selective publication of favorable results can create a skewed perception of drug efficacy and safety.

Opinion Leaders and Key Opinion Leaders (KOLs)

Influential clinicians are often engaged to advocate for specific antibiotics. Their recommendations can significantly shape prescribing trends across healthcare systems [19].

Conference Sponsorships

Industry-sponsored conferences provide platforms for promoting new antibiotics, often emphasizing innovation and clinical superiority. (Table 3)

Table 3. Classification of antibiotic promotion practices.

Category	Sub-type	Key characteristics	Potential impact
Direct Promotion	Medical detailing	One-on-one interaction	High influence on prescribing.
	CME sponsorship	Educational with promotional bias	Alters clinical perception.
	Free samples/incentives	Material benefits	Encourages drug preference.
Indirect Promotion	Journal advertising	Scientific appearance	Influences evidence interpretation.
	KOL endorsements	Authority-driven	Shapes large-scale prescribing trends.
	Conference sponsorships	Networking and exposure	Promotes new antibiotics.
Digital Promotion	Online ads, webinars	Wide reach, targeted	Rapid dissemination of promotional content.

Digital and Emerging Promotion Practices

The digital era has introduced novel promotional strategies that significantly expand the reach and impact of pharmaceutical marketing.

E-Detailing and Webinars

Digital platforms allow companies to present drug information remotely, increasing accessibility for healthcare professionals.

Social Media and Targeted Advertising

Algorithms enable targeted promotion based on clinician preferences, specialties, and prescribing history.

Mobile Applications

Apps designed for clinical decision support may include embedded promotional content, subtly influencing drug selection [14].

MECHANISTIC INSIGHTS: HOW PROMOTION INFLUENCES PHARMACOVIGILANCE AND RESISTANCE REPORTING

Understanding the mechanisms through which antibiotic promotion affects pharmacovigilance and resistance reporting is crucial for identifying intervention points.

Cognitive and Behavioral Mechanisms

Promotional practices influence clinician behavior through well-established psychological principles:

- *Reciprocity:* Acceptance of gifts or incentives creates a subconscious obligation to reciprocate through prescribing.
- *Anchoring Bias:* Initial exposure to a promoted antibiotic sets a reference point for future prescribing decisions.
- *Availability Heuristic:* Frequently promoted drugs are more readily recalled, increasing their likelihood of being prescribed.

These cognitive biases can also affect pharmacovigilance by altering clinicians' perception of drug safety. If a drug is perceived as safe due to repeated positive messaging, adverse events may be overlooked or attributed to other causes. [20]

Information Asymmetry and Selective Disclosure

Pharmaceutical promotion often involves selective presentation of data:

- Emphasis on positive clinical trial outcomes.
- Limited discussion of adverse effects.
- Underrepresentation of resistance risks.

This information asymmetry can lead to incomplete understanding among healthcare professionals, affecting both prescribing behavior and ADR reporting. [21]

Economic and System-Level Drivers

Economic incentives play a significant role in shaping healthcare practices:

- Hospitals may prefer certain antibiotics due to procurement agreements.
- Physicians may be influenced by financial or career-related benefits.
- Pharmaceutical companies prioritize high-revenue antibiotics.

These factors collectively contribute to increased use of promoted antibiotics, which may not always align with clinical guidelines or antimicrobial stewardship principles.

FORMULATION / DEVELOPMENT ASPECTS OF ANTIBIOTICS IN PROMOTION CONTEXT

Although formulation science primarily focuses on drug delivery, stability, and bioavailability, it also plays a significant role in shaping promotional narratives. Pharmaceutical companies often highlight formulation innovations as key differentiators in marketing antibiotics. [22]

Novel Drug Delivery Systems (NDDS) in Antibiotics

Advancements in drug delivery technologies have led to the development of innovative antibiotic formulations:

- Liposomal formulations.
- Nanoparticle-based delivery systems
- Sustained-release formulations.
- Targeted drug delivery systems.

These technologies are often promoted as offering superior efficacy, reduced toxicity, and improved patient compliance.

For instance, liposomal formulations of antibiotics aim to enhance drug penetration into infected tissues while minimizing systemic exposure.

Formulation-Based Promotional Claims

Promotional strategies frequently emphasize formulation advantages such as:

- Once-daily dosing for improved compliance.
- Enhanced bioavailability.
- Reduced side effects.
- Broad-spectrum coverage.

While these claims may be scientifically valid, they can also overshadow important considerations such as cost-effectiveness, resistance potential, and comparative efficacy with existing therapies.

Stability and Shelf-Life Considerations

Pharmaceutical companies often promote antibiotics with improved stability profiles, especially in regions with limited cold-chain infrastructure. This is particularly relevant in low- and middle-income countries, where storage conditions can affect drug efficacy.

However, stability advantages should not be conflated with clinical superiority. Misinterpretation of such claims can influence prescribing behavior and contribute to irrational antibiotic use. (Table 4)

Table 4. Role of formulation in antibiotic promotion.

Formulation feature	Promotional claim	Potential concern
Sustained-release	Reduced dosing frequency	Overuse due to convenience.
Liposomal delivery	Targeted action, reduced toxicity	High cost, limited evidence.
Broad-spectrum formulation	Effective against multiple pathogens	Increased resistance risk.
Improved stability	Suitable for varied environments	May overshadow clinical appropriateness.

Regulatory Oversight of Formulation Claims

Regulatory agencies require that promotional claims be supported by scientific evidence. However, enforcement varies across regions. In some cases, exaggerated claims regarding formulation benefits may influence prescribing without adequate validation.

This highlights the need for stricter regulatory scrutiny and independent evaluation of promotional content, particularly for novel antibiotic formulations [23].

EVALUATION / CHARACTERIZATION OF ANTIBIOTIC PROMOTION IMPACT

Evaluating the influence of antibiotic promotion practices requires a multidisciplinary approach combining pharmacovigilance data analysis, prescribing audits, resistance surveillance, and behavioral research. Unlike traditional pharmaceutical evaluation (e.g., physicochemical characterization), this domain focuses on health system-level metrics and outcomes.

Pharmacovigilance Data Analysis

Pharmacovigilance databases serve as primary tools for assessing drug safety signals. Organizations such as the Uppsala Monitoring Centre maintain global ADR reporting systems that can be analyzed for patterns associated with promoted antibiotics.

Key Parameters Evaluated:

- *Reporting Rate (RR):* Number of ADR reports per unit drug usage.
- *Proportional Reporting Ratio (PRR):* Comparison of ADR frequency with other drugs.
- *Signal Detection Metrics:* Identification of unexpected adverse events.

A decline in ADR reporting rates for heavily promoted antibiotics may indicate underreporting rather than improved safety.

Prescription Pattern Monitoring

Prescription audits provide direct insight into the impact of promotional practices. These studies analyze:

- Frequency of antibiotic prescriptions.
- Spectrum of antibiotics used (narrow vs broad).
- Adherence to treatment guidelines.
- Duration and dosing patterns.

For example, increased prescribing of antibiotics like Azithromycin in outpatient settings – often beyond guideline recommendations – has been linked to promotional influence. (Table 5)

Table 5. Indicators used in prescription pattern analysis.

Indicator	Description	Relevance
Prescription Frequency	Number of antibiotic prescriptions	Identifies overuse.
Drug Selection Pattern	Type of antibiotic prescribed	Detects bias toward promoted drugs.
Guideline Adherence	Compliance with standard protocols	Measures rational use.
Duration of Therapy	Length of antibiotic treatment	Identifies misuse.

Antimicrobial Resistance Surveillance

Resistance surveillance systems track the emergence and spread of resistant organisms. These systems are often coordinated by global bodies such as the World Health Organization under initiatives like GLASS (Global Antimicrobial Resistance Surveillance System) [24].

Key Evaluation Metrics:

- Resistance rates of specific pathogens.
- Trends in susceptibility patterns.
- Geographic distribution of resistance.
- Correlation with antibiotic consumption.

An increase in resistance to commonly promoted antibiotics suggests a direct link between marketing-driven usage and microbial adaptation.

Behavioral and Qualitative Assessments

Understanding the psychological and behavioral aspects of prescribing requires qualitative research methods:

- Surveys of healthcare professionals.
- Interviews and focus groups.
- Observational studies of clinical practice.

These methods help identify:

- Awareness of pharmacovigilance systems.
- Perception of drug safety.
- Influence of promotional activities.
- Barriers to ADR reporting.

Applications of Understanding Promotion Influence

Analyzing the impact of antibiotic promotion has several practical applications in healthcare systems:

Strengthening Antimicrobial Stewardship Programs

Antimicrobial stewardship programs (ASPs) aim to optimize antibiotic use and reduce resistance. By identifying promotional influences, ASPs can:

- Develop targeted educational interventions.
- Restrict inappropriate antibiotic use.
- Promote guideline adherence.

Pharmacovigilance Systems

Insights into reporting biases can help improve pharmacovigilance by:

- Encouraging active surveillance methods.
- Integrating electronic reporting systems.
- Training healthcare professionals.

Policy Development and Regulation

Regulatory authorities can use evidence from such analyses to:

- Enforce ethical marketing practices.
- Monitor pharmaceutical advertising.
- Implement stricter approval processes for promotional materials.

Public Health Planning

Understanding resistance patterns influenced by promotion helps in:

- Designing national antibiotic policies.
- Allocating healthcare resources.
- Planning infection control strategies (Table 6).

Table 6. Applications of research on antibiotic promotion.

Application area	Benefit	Outcome
Antimicrobial Stewardship	Rational antibiotic use	Reduced resistance.
Pharmacovigilance Enhancement	Improved ADR reporting	Better drug safety.
Regulatory Policy	Ethical promotion control	Reduced bias.
Public Health Planning	Data-driven decisions	Improved healthcare outcomes.

Advantages of Regulating Antibiotic Promotion

- Promotes rational prescribing practices.
- Enhances patient safety through better ADR reporting.
- Reduces emergence and spread of antimicrobial resistance.
- Improves reliability of pharmacovigilance databases.
- Supports evidence-based medicine.

Limitations and Challenges

Despite the importance of addressing antibiotic promotion, several challenges persist:

Underreporting of ADRs

Even in well-established systems, underreporting remains a major issue due to:

- Lack of awareness.
- Time constraints.
- Fear of legal consequences.

Weak Regulatory Frameworks

In many developing regions, inadequate enforcement of promotional guidelines allows unethical practices to continue.

Data Integration Issues

Pharmacovigilance and resistance surveillance systems often operate independently, limiting comprehensive analysis [10, 11].

Future Perspectives

Addressing the influence of antibiotic promotion on pharmacovigilance and resistance reporting requires a multifaceted and forward-looking approach.

Strengthening Regulatory Frameworks

Regulatory authorities must enforce stricter guidelines for pharmaceutical promotion, ensuring:

- Transparency in marketing practices.
- Balanced presentation of efficacy and safety data.
- Penalties for unethical promotion.
- Global coordination led by organizations such as the World Health Organization can help standardize these efforts.

Integration of Digital Pharmacovigilance

The adoption of digital technologies offers new opportunities:

- Real-time ADR reporting through mobile applications.
- Integration of electronic health records (EHRs).
- Use of artificial intelligence for signal detection.

These advancements can improve reporting accuracy and reduce delays in identifying safety concerns.

CONCLUSION

The influence of antibiotic promotion practices on pharmacovigilance and resistance reporting patterns represents a complex and multifactorial challenge in modern healthcare. While pharmaceutical promotion plays a legitimate role in disseminating drug-related information, its impact on prescribing behavior, ADR reporting, and resistance development cannot be overlooked.

This review highlights that promotional practices can introduce biases at multiple levels – cognitive, behavioral, and systemic – leading to irrational antibiotic use and compromised pharmacovigilance systems. The resulting underreporting of adverse drug reactions and delayed detection of resistance trends pose significant risks to patient safety and public health.

Addressing these challenges requires a coordinated effort involving regulatory authorities, healthcare professionals, researchers, and international organizations. Strengthening pharmacovigilance systems, promoting antimicrobial stewardship, ensuring ethical marketing practices, and leveraging digital technologies are critical steps toward mitigating the adverse effects of antibiotic promotion.

Ultimately, achieving a balance between pharmaceutical innovation and public health priorities is essential to combat antimicrobial resistance and ensure the safe and effective use of antibiotics for future generations.

REFERENCES

1. World Health Organization. Global action plan on antimicrobial resistance. Geneva: World Health Organization; 2015.
2. Paneri M, Sevta P. Overview of antimicrobial resistance: An emerging silent pandemic. Glob J Med Pharm Biomed Update. 2023;18.
3. More SA, Atal S, Mishra PS. Inter-rater agreement between WHO-Uppsala Monitoring Centre system and Naranjo algorithm for causality assessment of adverse drug reactions. J Pharmacol Toxicol Methods. 2024;127:107514.
4. World Health Organization. Active tuberculosis drug-safety monitoring and management (aDSM): Framework for implementation. Geneva: World Health Organization; 2015.
5. Menebo MM. Smart advertising in prescription only medication: Aligning it with prescriber's or consumer's behavior. Int J Pharm Healthc Mark. 2022;16(1):55–74.
6. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: A systematic review. PLoS Med. 2010;7(10):e1000352.
7. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. 2016.
8. Ventola CL. The antibiotic resistance crisis: Part 1: Causes and threats. Pharm Ther. 2015;40(4):277.
9. Belleudi V, Fortinguerra F, Poggi FR, Perna S, Bortolus R, Donati S, et al. The Italian network for monitoring medication use during pregnancy (MoM-Net): Experience and perspectives. Front Pharmacol. 2021;12:699062.
10. Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA. 2000;283(3):373–80.
11. Norris P, Herxheimer A, Lexchin J, Mansfield P. Drug promotion: What we know, what we have yet to learn: Reviews of materials in the WHO/HAI database on drug promotion. In: Drug promotion: What we know, what we have yet to learn. 2005. p. x–92.

12. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance—The need for global solutions. Lancet Infect Dis. 2013;13(12):1057–98.
13. Holloway K, Van Dijk L. The world medicines situation 2011: Rational use of medicines. Geneva: World Health Organization; 2011.
14. Fugh-Berman A, Ahari S. Following the script: How drug reps make friends and influence doctors. PLoS Med. 2007;4(4):e150.
15. Sismondo S, Doucet M. Publication ethics and the ghost management of medical publication. Bioethics. 2010;24(6):273–83.
16. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001;110(7):551–7.
17. Richter L, Du Plessis EM, Duvenage S, Korsten L. Occurrence, identification, and antimicrobial resistance profiles of extended-spectrum and AmpC β-lactamase-producing Enterobacteriaceae from fresh vegetables retailed in Gauteng Province, South Africa. Foodborne Pathog Dis. 2019;16(6):421–7.
18. Kumawat M, Khandelwal O, Agrawal P, Pradhan P, Sharma O. Herbal medicine and pharmacy practice: Roles, challenges, and future pathways. J Ayurveda Herb Sci. 2026;1(1):10–45.
19. Haque M, Sartelli M, McKimm J, Bakar MA. Health care-associated infections–an overview. Infect Drug Resist. 2018;11:2321–33.
20. Kadri SS. Key takeaways from the US CDC's 2019 antibiotic resistance threats report for frontline providers. Crit Care Med. 2020;48(7):939–45.
21. Sultana J, Zaccaria C, De Lisa R, Rossi F, Capuano A, Ferrajolo C. Good pharmacovigilance practice in paediatrics: An overview of the updated European Medicines Agency guidelines. Pediatr Drugs. 2019;21(5):317–21.
22. Godman B, Haque M, McKimm J, Abu Bakar M, Sneddon J, Wale J, et al. Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: Findings and implications for the future. Curr Med Res Opin. 2020;36(2):301–327.
23. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Evid Based Child Health. 2006;1(2):623–90.
24. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742–50.

